Securities Code：4521
Supplementary Financial Information |
Consolidated Financial Results for the Three Months Period June 30, 2025 |
August 7, 2025
目次
1. | Summary of Consolidated Financial Statements for the Three Months Period June 30, 2025 |
2. | Consolidated Net Sales by Segment |
3. | Consolidated Overseas Sales |
4. | Consolidated Capital Expenditures, and Depreciation and Amortization |
5. | Summary of Consolidated Balance Sheet |
6. | Summary of Non-consolidated Financial Statements for the Three Months Period June 30, 2025 |
7. | Non-consolidated Detailed Sales Breakdown |
8. | Non-consolidated Overseas Sales |
9. | Non-consolidated Capital Expenditures, and Depreciation and Amortization |
10. | Sales of Major Domestic Pharmaceuticals and Medical Devices (Non-consolidated) |
11. | Pipelines |
12. | Status of Out-Licensed Products Overseas |
p.２ |
p.２ |
p.3 |
p.3 |
p.4 |
p.5 |
p.5 |
p.6 |
p.6 |
p.7 |
p.8 |
p.9 |
Cautionary notes regarding forward-looking statement |
・This information contains forward-looking statements on the Kaken group's business. ・They are projections based on information available at the time this information was prepared, and may differ from actual results due to a variety of facto ・In addition, although this information includes information related to pharmaceutical products (including those under development), these statements are not intended to be advertisement or medical advice. |
1． Summary of Consolidated Financial Statements for the Three Months Period June 30, 2025 | ||||||||||
(amounts are rounded down to the nearest million Yen) | ||||||||||
FY2024 1Q | FY2024 | FY2025 1Q | Change (yen) | Change (%) | Plan 2025 | Change (yen) | Change (%) | |||
Net sales | 18,254 | 94,035 | 18,867 | 613 | 103.4% | 88,000 | ▲ 6,035 | 93.6% | ||
Cost of sales | 8,202 | 35,502 | 8,995 | 793 | 109.7% | ー | ー | ー | ||
Gross profit | 10,052 | 58,532 | 9,872 | ▲ 179 | 98.2% | ー | ー | ー | ||
Ratio to net sales | 55.1% | 62.2% | 52.3% | ー | ||||||
Selling, general and administrative expenses | 7,301 | 37,497 | 9,858 | 2,556 | 135.0% | 44,500 | 7,002 | 118.7% | ||
R&D expenses | 2,998 | 18,725 | 5,382 | 2,384 | 179.5% | 20,900 | 2,174 | 111.6% | ||
Operating profit | 2,750 | 21,034 | 14 | ▲ 2,736 | 0.5% | 5,200 | ▲ 15,834 | 24.7% | ||
Ratio to net sales | 15.1% | 22.4% | 0.1% | 5.9% | ||||||
Ordinary profit | 3,011 | 21,279 | 417 | ▲ 2,593 | 13.9% | 6,000 | ▲ 15,279 | 28.2% | ||
Ratio to net sales | 16.5% | 22.6% | 2.2% | 6.8% | ||||||
Profit before income taxes | 2,371 | 19,435 | 409 | ▲ 1,962 | 17.3% | ー | ー | ー | ||
Profit | 1,754 | 13,945 | 271 | ▲ 1,483 | 15.5% | 3,400 | ▲ 10,545 | 24.4% | ||
Ratio to net sales | 9.6% | 14.8% | 1.4% | 3.9% | ||||||
Per share profit (Yen) | 46.32 | 365.42 | 7.13 |
88.53
Consolidated Net Sales by Segment
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Pharmaceuticals
17,643
91,553
18,229
586
103.3%
Pharmaceuticals & medical devices
16,991
85,734
17,070
78
100.5%
Crop protection
632
5,717
1,108
476
175.3%
Others
19
101
50
31
265.4%
Real estate
611
2,481
638
27
104.4%
Total
18,254
94,035
18,867
613
103.4%
Plan 2025
Change (yen)
Change (%)
85,500
▲ 6,053
93.4%
79,000
▲ 6,734
92.1%
6,400
682
111.9%
100
▲ 1
98.9%
2,500
18
100.7%
88,000
▲ 6,035
93.6%
Consolidated Overseas Sales
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Pharmaceuticals
872
23,847
1,462
589
167.5%
Crop protection
119
2,761
316
197
265.7%
Export volume
992
26,609
1,779
787
179.3%
Overseas Sales Ratio
5.4%
28.3%
9.4%
Plan 2025
Change (yen)
Change (%)
20,400
▲ 3,447
85.5%
3,200
438
115.9%
23,600
▲ 3,009
88.7%
26.8%
Consolidated Capital Expenditures, and Depreciation and Amortization
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Capital expenditures
2,014
3,418
1,417
▲ 596
70.4%
Depreciation and amortization
638
2,475
618
▲ 19
96.9%
Plan 2025
Change (yen)
Change (%)
5,300
1,881
155.0%
2,800
324
113.1%
Summary of Consolidated Balance Sheet
As of June 30, 2024 | As of March 31, 2025 | As of June 30, 2025 | YoY Increase (Decrease) | |
Total assets | 174,777 | 190,422 | 176,341 | 1,564 |
Current assets | 109,073 | 111,377 | 96,634 | ▲ 12,438 |
Cash and Cash Equivalents | 66,562 | 70,085 | 55,404 | ▲ 11,157 |
Notes and accounts receivable - trade, and contract assets | 24,556 | 21,178 | 21,627 | ▲ 2,928 |
Inventories | 17,088 | 19,021 | 18,508 | 1,420 |
Non-current assets | 65,704 | 79,045 | 79,707 | 14,003 |
Property, plant and equipment | 26,792 | 27,629 | 28,455 | 1,663 |
Intangible assets | 7,397 | 19,289 | 19,308 | 11,911 |
Goodwill | - | 14,035 | 14,016 | 14,016 |
Investments and other assets | 31,514 | 32,126 | 31,942 | 427 |
Total liabilities | 32,257 | 37,787 | 28,894 | ▲ 3,362 |
Current liabilities | 23,101 | 30,354 | 21,842 | ▲ 1,259 |
Notes and Accounts Payable, etc. | 7,395 | 8,323 | 6,346 | ▲ 1,049 |
Accounts payable-other | 4,290 | 6,311 | 4,752 | 461 |
Non-current liabilities | 9,155 | 7,433 | 7,051 | ▲ 2,103 |
Total net assets | 142,520 | 152,634 | 147,447 | 4,927 |
Common stock | 23,853 | 23,853 | 23,853 | ー |
Capital surplus | 11,462 | 12,932 | 11,406 | ▲ 55 |
Retained earnings | 127,418 | 135,242 | 127,368 | ▲ 49 |
Treasury stock | ▲ 28,614 | ▲ 28,233 | ▲ 23,791 | 4,822 |
(amounts are rounded down to the nearest million Yen)
* Goodwill from prior fiscal years is included in "Other".
6．Summary of Non-consolidated Financial Statements for the Three Months Period June 30, 2025 | ||||||||||
(amounts are rounded down to the nearest million Yen) | ||||||||||
FY2024 1Q | FY2024 | FY2025 1Q | Change (yen) | Change (%) | Plan 2025 | Change (yen) | Change (%) | |||
Net sales | 18,235 | 93,934 | 18,817 | 582 | 103.2% | 84,900 | ▲ 9,034 | 90.4% | ||
Cost of sales | 8,235 | 35,595 | 9,012 | 776 | 109.4% | ー | ー | ー | ||
Gross profit | 9,999 | 58,338 | 9,804 | ▲ 194 | 98.1% | ー | ー | ー | ||
Ratio to net sales | 54.8% | 62.1% | 52.1% | ー | ||||||
Selling, general and administrative expenses | 7,229 | 35,815 | 9,770 | 2,541 | 135.1% | 38,700 | 2,884 | 108.1% | ||
R&D expenses | 2,998 | 18,725 | 5,382 | 2,384 | 179.5% | 20,600 | 1,874 | 110.0% | ||
Operating profit | 2,769 | 22,522 | 33 | ▲ 2,735 | 1.2% | 8,100 | ▲ 14,422 | 36.0% | ||
Ratio to net sales | 15.2% | 24.0% | 0.2% | 9.5% | ||||||
Ordinary profit | 3,031 | 22,766 | 437 | ▲ 2,593 | 14.4% | 8,800 | ▲ 13,966 | 38.7% | ||
Ratio to net sales | 16.6% | 24.2% | 2.3% | 10.4% | ||||||
Profit before income taxes | 2,391 | 22,370 | 428 | ▲ 1,962 | 17.9% | ー | ー | ー | ||
Profit | 1,775 | 16,449 | 293 | ▲ 1,482 | 16.5% | 6,100 | ▲ 10,349 | 37.1% | ||
Ratio to net sales | 9.7% | 17.5% | 1.6% | 7.2% | ||||||
Per share profit (Yen) | 46.89 | 431.06 | 7.71 |
158.84 |
Non-consolidated Detailed Sales Breakdown
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Pharmaceuticals & medical devices
16,991
85,734
17,070
78
100.5%
Crop protection
632
5,717
1,108
476
175.3%
Real estate
611
2,481
638
27
104.4%
Total
18,235
93,934
18,817
582
103.2%
Plan 2025
Change (yen)
Change (%)
76,000
▲ 9,734
88.6%
6,400
682
111.9%
2,500
18
100.7%
84,900
▲ 9,034
90.4%
Non-consolidated Overseas Sales
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Pharmaceuticals
864
23,798
1,431
566
165.5%
Crop protection
110
2,647
275
165
249.7%
Export volume
975
26,446
1,706
731
175.0%
Overseas Sales Ratio
5.3%
28.2%
9.1%
Plan 2025
Change (yen)
Change (%)
17,400
▲ 6,398
73.1%
3,200
552
120.9%
20,600
▲ 5,846
77.9%
24.3%
Non-consolidated Capital Expenditures, and Depreciation and Amortization
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Capital expenditures
2,014
3,418
1,416
▲ 597
70.3%
Depreciation and amortization
638
2,475
618
▲ 19
96.9%
Plan 2025
Change (yen)
Change (%)
5,300
1,881
155.0%
2,800
324
113.1%
Sales of Major Domestic Pharmaceuticals and Medical Devices (Non-consolidated)
(amounts are rounded down to the nearest million Yen)
FY2024 1Q
FY2024
FY2025 1Q
Change (yen)
Change (%)
Onychomycosis treatment
Clenafin group
4,495
16,866
4,377
▲ 118
97.4%
Anti-osteoarthritis agent
Artz
4,912
19,031
4,614
▲ 297
94.0%
Post-operative anti-adhesive
Seprafilm
1,724
6,952
1,729
4
100.3%
Wound-healing agent
Fiblast
626
2,432
565
▲ 60
90.3%
Primary axillary hyperhidrosis treatment
Ecclock
681
2,037
803
121
117.9%
Periodontal regenerative agent
Regroth
233
922
220
▲ 12
94.8%
Lumbar disc herniation treatment
Hernicore
104
405
78
▲ 26
75.2%
Generic products (total)
2,062
8,497
1,824
▲ 237
88.5%
Plan 2025
Change (yen)
Change (%)
13,200
▲ 3,666
78.3%
18,500
▲ 531
97.2%
7,000
47
100.7%
2,300
▲ 132
94.6%
2,400
362
117.8%
1,000
77
108.4%
400
▲ 5
98.8%
8,900
402
104.7%
-
Pipelines As of August 7, 2025
＜In-house discovered and in-licensed projects＞ (*) The development stage includes the preparatory period for clinical trials.
Development code
Planned Indication
Development
Stage *
In-house/In-licensed
Remarks
KAR
Head lice
P III
Arbor Pharmaceuticals, LLC
Product name in the US: Sklice
KP-001
Refractory vascular malformations
P III
Product discovered in-house
ー
KC-8025
Primary biliary cholangitis
P III
CymaBay Therapeutics, Inc. (Currently, Gilead Sciences, Inc.)
Product name in US,UK：Livdelzi®
Product name in EU : Lyvdelzi®
Generic Name：Seladelpar
ESK-001
Plaque psoriasis
P III
Alumis Inc.
Under global P III (incl. Japan)
KP-483
Solid tumors (Immuno-oncology)
P I
Product discovered in-house
ー
KP-910
Peripheral neuropathic pain
P I
Product discovered in-house
ー
Tildacerfont
Congenital adrenal hyperplasia
P I
Spruce Biosciences, Inc.
ー
KP-001 (US)
Refractory vascular malformations
P I
Product discovered in-house
Consulting with FDA on P III plan
Note: Kaken will advance KP-723, an oral STAT6 inhibitor in preclinical development, to the completion of Phase I clinical trials, which had entered into a licence agreement with J&J.
＜Other＞
Development code
Planned Indication
Development Stage
Remarks
Sebetralstat
Hereditary angioedema
Authorization application
・Applied by KalVista Pharmaceuticals, Inc.
・Obtained approval from FDA（Product name in the US：Ekterly®）
・Exclusive sales rights in Japan
gMSC1
Knee osteoarthritis with focal defect
Preparing for P III
・Allogenic synovial mesenchymal stem cell-derived
three-dimensional artificial tissue
・Development by the licensor, TWOCELLS Co., Ltd.
・Joint development and exclusive sales rights in the field of orthopedics
in Japan
NM26
Atopic dermatitis
P II
・Clinical trial underway by J&J after IP transfer
・Option rights to negotiate a sales partnership agreement in Japan
Note: The medical device "Silk-Elastin Wound Healing Sheet", for which a marketing authorization application had been submitted by the licensor,
Sanyo Chemical Industries, Ltd., was approved on April 21, 2025.
Status of Out-Licensed Products Overseas
As of August 7, 2025 | ||||
Generic name (domestic sales name) | Planned indication | Development Stage | Out-licensed | Developing country |
Efinaconazole (Clenafin) | Onychomycosis | Authorization application | Almirall S.A. | Germany (Italy: Approved in Mar 2025) |
Efinaconazole (Clenafin) | Onychomycosis | P III | AIM | China |
Sofpironium bromide (Ecclock) | Primary axillary hyperhidrosis | Authorization application | Dong-Wha Pharm Co., Ltd. | Korea |